Cargando…

PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease

BACKGROUND: The incidence of thyroid cancer in the United States and worldwide has increased 300% over the last three decades.1 Graves’ disease (GD) is the most common cause of hyperthyroidism. GD occurs due to activating antibodies to the TSH receptor. Thyroid-stimulating antibodies can result in i...

Descripción completa

Detalles Bibliográficos
Autores principales: Panthi, Sujata, Crow, Hanna M, Bantis, Leonidas, Choudhary, Chitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628795/
http://dx.doi.org/10.1210/jendso/bvac150.1749
_version_ 1784823263218630656
author Panthi, Sujata
Crow, Hanna M
Bantis, Leonidas
Choudhary, Chitra
author_facet Panthi, Sujata
Crow, Hanna M
Bantis, Leonidas
Choudhary, Chitra
author_sort Panthi, Sujata
collection PubMed
description BACKGROUND: The incidence of thyroid cancer in the United States and worldwide has increased 300% over the last three decades.1 Graves’ disease (GD) is the most common cause of hyperthyroidism. GD occurs due to activating antibodies to the TSH receptor. Thyroid-stimulating antibodies can result in intrinsic and genetic factors to favor the tumor growth process.2 Recent studies show that the incidence of thyroid cancer is higher among patients with GD when compared to toxic multinodular goiter.3 The current study compares the outcomes of Differentiated Thyroid Cancer (DTC) in patients with GD with non-GD patients. OBJECTIVE: The aim of the study was to compare demographics, pathology, stage, and prognosis of DTC in patients with GD with non-GD patients. METHODS: This was a retrospective chart review of 42 patients with a diagnosis of DTC with or without GD. Patients were selected using HERON (Healthcare Enterprise Repository Ontological Narration) software. We compared age at diagnosis, type and size of the tumor, radioactive iodine (RAI) use, and DTC recurrence amongst patients with GD with non-GD patients. We used the Chi-square to test for independence among the categorical variables at a nominal level of 0.05. The comparison of continuous variables was based on the t-test. RESULTS: The mean age of patients was 50 years (range 23–86). Out of 42 patients, 29 patients had GD and 13 patients did not have GD. 92% had papillary thyroid cancer and the mean tumor size was 1.3 cm (range 0.09–7.5). 86% of the patients had Stage 1 and 2 DTC. Patients with GD were diagnosed with DTC at a younger age (mean age 46 years) when compared to the patients without GD (mean age 59 years) with a p-value of 0.013. There was no difference in patients with GD in regard to the type of DTC (P = 0.54) and the stage of DTC (p-value 0.139). Both groups of patients had a similar rate of recurrence and RAI use (Table). CONCLUSION: The current study concludes that patients with GD were diagnosed with DTC at an earlier age when compared to patients without GD. The stage of DTC and recurrence rate were similar in the two groups. The study was limited to a small number of patients. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.
format Online
Article
Text
id pubmed-9628795
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96287952022-11-04 PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease Panthi, Sujata Crow, Hanna M Bantis, Leonidas Choudhary, Chitra J Endocr Soc Thyroid BACKGROUND: The incidence of thyroid cancer in the United States and worldwide has increased 300% over the last three decades.1 Graves’ disease (GD) is the most common cause of hyperthyroidism. GD occurs due to activating antibodies to the TSH receptor. Thyroid-stimulating antibodies can result in intrinsic and genetic factors to favor the tumor growth process.2 Recent studies show that the incidence of thyroid cancer is higher among patients with GD when compared to toxic multinodular goiter.3 The current study compares the outcomes of Differentiated Thyroid Cancer (DTC) in patients with GD with non-GD patients. OBJECTIVE: The aim of the study was to compare demographics, pathology, stage, and prognosis of DTC in patients with GD with non-GD patients. METHODS: This was a retrospective chart review of 42 patients with a diagnosis of DTC with or without GD. Patients were selected using HERON (Healthcare Enterprise Repository Ontological Narration) software. We compared age at diagnosis, type and size of the tumor, radioactive iodine (RAI) use, and DTC recurrence amongst patients with GD with non-GD patients. We used the Chi-square to test for independence among the categorical variables at a nominal level of 0.05. The comparison of continuous variables was based on the t-test. RESULTS: The mean age of patients was 50 years (range 23–86). Out of 42 patients, 29 patients had GD and 13 patients did not have GD. 92% had papillary thyroid cancer and the mean tumor size was 1.3 cm (range 0.09–7.5). 86% of the patients had Stage 1 and 2 DTC. Patients with GD were diagnosed with DTC at a younger age (mean age 46 years) when compared to the patients without GD (mean age 59 years) with a p-value of 0.013. There was no difference in patients with GD in regard to the type of DTC (P = 0.54) and the stage of DTC (p-value 0.139). Both groups of patients had a similar rate of recurrence and RAI use (Table). CONCLUSION: The current study concludes that patients with GD were diagnosed with DTC at an earlier age when compared to patients without GD. The stage of DTC and recurrence rate were similar in the two groups. The study was limited to a small number of patients. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9628795/ http://dx.doi.org/10.1210/jendso/bvac150.1749 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Thyroid
Panthi, Sujata
Crow, Hanna M
Bantis, Leonidas
Choudhary, Chitra
PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
title PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
title_full PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
title_fullStr PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
title_full_unstemmed PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
title_short PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
title_sort psat380 characteristics and prognosis of differentiated thyroid cancer in patients with graves disease
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628795/
http://dx.doi.org/10.1210/jendso/bvac150.1749
work_keys_str_mv AT panthisujata psat380characteristicsandprognosisofdifferentiatedthyroidcancerinpatientswithgravesdisease
AT crowhannam psat380characteristicsandprognosisofdifferentiatedthyroidcancerinpatientswithgravesdisease
AT bantisleonidas psat380characteristicsandprognosisofdifferentiatedthyroidcancerinpatientswithgravesdisease
AT choudharychitra psat380characteristicsandprognosisofdifferentiatedthyroidcancerinpatientswithgravesdisease